FDA warns Empower Pharmacy that insanitary conditions in sterile drug compounding put patients at risk.
What happened
FDA inspected the Houston facility from September 24 to October 4, 2024, and issued a Form FDA 483, FDA's list of inspection observations, on October 4, 2024. FDA said investigators found serious deficiencies in sterile drug production: environmental monitoring did not sample the critical filling area, media fills were not run under worst-case conditions, and equipment in the ISO 5 (high-cleanliness) area was not properly sterilized. FDA reviewed the company's responses dated October 28, 2024, and January 31, 2025, and said some corrective actions were incomplete or lacked enough documentation.
What FDA found
FDA cited the firm for not adequately monitoring air in the critical filling area where sterile drugs are exposed.
FDCA section 501(a)(2)(A), 21 U.S.C. § 351(a)(2)(A)FDA cited the firm because its media fills (test runs using growth medium instead of drug) were not performed under the most challenging conditions, so it lacked assurance of aseptic (sterile) production.
FDCA section 501(a)(2)(A), 21 U.S.C. § 351(a)(2)(A)FDA cited the firm for not properly sterilizing the stopper sorting bowl, supply hopper, and insertion station in the ISO 5 area that contact stoppers used for injectable drugs.
FDCA section 501(a)(2)(A), 21 U.S.C. § 351(a)(2)(A)
What FDA wants
FDA asks the company to respond in writing within 15 working days with specific corrective steps, an explanation of how it will prevent recurrence, and supporting documents. FDA also strongly recommends a comprehensive assessment of operations, including aseptic processing, with a third-party sterile manufacturing expert.
Who should pay attention
- patients and clinics that receive compounded sterile injectables from this pharmacy
- compounding pharmacies and sterile manufacturers with similar aseptic operations
- healthcare providers who prescribe or administer compounded injectable drugs
This is a summary. Read the original letter on fda.gov.